hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 20:51:50 - browse：6

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： For Medicare Advantage, Democrats want stronger protections around AI

WSS

PhRMA lawsuit over Medicare drug price negotiation tossed

The Readout: Gilead, Bernie Sanders, and other pharma news

Extensive review finds private equity owners jack up cost of care

Senators start work on Medicare physician payment reform

Dementia risk linked to living in disadvantaged areas: Study

The Readout: Gilead, Bernie Sanders, and other pharma news

knowledge

hotspot

explore

Cancer drug shortages should be causing more outrage

To avoid data mishandling cases, universities eye AI and other tools

Dobbs anniversary: the lost opportunity of abortion as health care

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

23andMe had bad news about my health. I wish a person had delivered it

After a decade, new Gardasil ad campaign gets it (mostly) right

Heart attack and stroke risk calculators need revising

'Revelatory' study finds a smoking impact that remains after quitting

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Delta passengers in Vegas fall sick while waiting on flight in triple

focus

For Medicare Advantage, Democrats want stronger protections around AI

Medicare threatens to cut off funding for HCA's Mission hospital

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

The dental labor crisis is a moment of opportunity

Dementia risk linked to living in disadvantaged areas: Study

entertainment

Wikipedia

focus

knowledge